Timothy Synold
Overview
Explore the profile of Timothy Synold including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
280
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Eroglu Z, Synold T, Badie B, Liu A, Chowdhury A, Kilpatrick J, et al.
Cancer Chemother Pharmacol
. 2024 Oct;
94(6):807-813.
PMID: 39422741
Purpose: Eribulin is an inhibitor of microtubule dynamics. It is not as highly protein bound as the taxanes and is less vulnerable to extrusion by P-glycoprotein in the blood-brain barrier...
2.
Christner S, Parise R, Bakkenist C, Davis S, Feng Y, Synold T, et al.
Biomed Chromatogr
. 2024 Oct;
38(12):e6024.
PMID: 39379043
The DNA-dependent protein kinase (DNA-PK) is an abundant nuclear protein that mediates DNA double-strand break repair by nonhomologous end joining (NHEJ). As such, DNA-PK is critical for V(D)J recombination in...
3.
Orleni M, Parise R, Holleran J, Amengual J, Feng Y, Synold T, et al.
Biomed Chromatogr
. 2024 May;
38(7):e5903.
PMID: 38783541
To support a phase 1 trial in patients with lymphomas, we developed a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for tazemetostat quantitation in 20 μL of human plasma. After protein...
4.
Lustberg M, Fan-Havard P, Wong F, Hill K, Phelps M, Herrera K, et al.
Breast Cancer Res Treat
. 2024 Jan;
205(1):61-73.
PMID: 38280052
Purpose: Aromatase inhibitor (AI) therapy reduces risk of recurrence and death for postmenopausal women with breast cancer (BC); however, AI-induced arthralgia (AIIA) can lead to discontinuation of treatment. Curcumin, a...
5.
Cristea M, Stewart D, Synold T, Ruel N, Mortimer J, Wang E, et al.
Gynecol Oncol
. 2024 Jan;
182:124-131.
PMID: 38262235
Objective: Platinum-resistant epithelial ovarian cancer (EOC), recurrent endometrial cancer (EC), and triple negative breast cancer (TNBC) are difficult to treat after failing standard therapies. This phase I study evaluated mirvetuximab...
6.
Emond R, Griffiths J, Grolmusz V, Nath A, Chen J, Medina E, et al.
Nat Commun
. 2023 Jun;
14(1):3851.
PMID: 37386030
The interplay of positive and negative interactions between drug-sensitive and resistant cells influences the effectiveness of treatment in heterogeneous cancer cell populations. Here, we study interactions between estrogen receptor-positive breast...
7.
Ji J, Sun C, Cohen H, Synold T, Muss H, Sedrak M
J Clin Oncol
. 2022 Sep;
41(2):307-315.
PMID: 36126235
Purpose: Older breast cancer survivors are at increased risk of clinical decline after adjuvant chemotherapy. This study aimed to evaluate whether inflammatory markers assessed before adjuvant chemotherapy are associated with...
8.
Ali H, Tsai N, Synold T, Mokhtari S, Tsia W, Palmer J, et al.
Blood Adv
. 2021 Sep;
6(5):1444-1453.
PMID: 34581764
We report results of our prospective pilot trial evaluating safety/feasibility of peritransplantation ruxolitinib for myelofibrosis treatment. Primary objectives were to determine safety and maximum tolerated dose (MTD) of ruxolitinib. Ruxolitinib...
9.
Dorff T, Stein C, Kortylewski M, Posadas E, Synold T, Quinn D
Cancer Biother Radiopharm
. 2020 May;
35(7):485-489.
PMID: 32366119
The effects of radium-223 on the immune system and the bone tumor microenvironment are incompletely understood. The authors describe mechanisms by which radium-223 may interact with the immune system, specifically...
10.
Kanaya N, Chang G, Wu X, Saeki K, Bernal L, Shim H, et al.
Commun Biol
. 2019 Nov;
2:406.
PMID: 31701034
Menopause is a critical window of susceptibility for its sensitivity to endocrine disrupting chemicals due to the decline of endogenous estrogen. Using a surgical menopausal (ovariectomized) mouse model, we assessed...